JPS63132834A - 鎮静剤製剤 - Google Patents
鎮静剤製剤Info
- Publication number
- JPS63132834A JPS63132834A JP62278987A JP27898787A JPS63132834A JP S63132834 A JPS63132834 A JP S63132834A JP 62278987 A JP62278987 A JP 62278987A JP 27898787 A JP27898787 A JP 27898787A JP S63132834 A JPS63132834 A JP S63132834A
- Authority
- JP
- Japan
- Prior art keywords
- tizanidine
- ibuprofen
- treatment
- pain
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic effect Effects 0.000 title description 8
- 239000003814 drug Substances 0.000 title description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 32
- 229960001680 ibuprofen Drugs 0.000 claims description 32
- 229960000488 tizanidine Drugs 0.000 claims description 25
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000036407 pain Effects 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 230000036592 analgesia Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 9
- 239000013543 active substance Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 208000008765 Sciatica Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 238000000876 binomial test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- -1 ESfl Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002388 tizanidine hydrochloride Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3637240.4 | 1986-11-03 | ||
| DE3637240 | 1986-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63132834A true JPS63132834A (ja) | 1988-06-04 |
Family
ID=6312966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62278987A Pending JPS63132834A (ja) | 1986-11-03 | 1987-11-02 | 鎮静剤製剤 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS63132834A (da) |
| KR (1) | KR890007728A (da) |
| AU (1) | AU8057587A (da) |
| BE (1) | BE1000265A3 (da) |
| DD (1) | DD300508A5 (da) |
| DK (1) | DK574187A (da) |
| FR (1) | FR2605884B1 (da) |
| GB (1) | GB2197198A (da) |
| GR (1) | GR871678B (da) |
| HU (1) | HUT47849A (da) |
| IL (1) | IL84344A0 (da) |
| IT (1) | IT8748554A0 (da) |
| LU (1) | LU87033A1 (da) |
| NL (1) | NL8702523A (da) |
| PH (1) | PH23276A (da) |
| PT (1) | PT86061B (da) |
| SE (1) | SE8704240L (da) |
| ZA (1) | ZA878257B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260337A (en) * | 1992-07-29 | 1993-11-09 | Merck & Co., Inc. | Ibuprofen-muscle relaxant combinations |
| US20040122065A1 (en) * | 2002-11-12 | 2004-06-24 | Lerner E. Itzhak | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally |
| TR200703092A1 (tr) | 2007-05-08 | 2008-12-22 | SANOVEL �LA� SAN. VE TiC. A.�. | Flurbiprofen ve kas gevşetici kombinasyonları |
| AU2013252491A1 (en) * | 2012-04-27 | 2014-11-06 | Troy Laboratories Pty Ltd | Combination meloxicam and xylazine therapy in animals |
| WO2016012398A1 (en) | 2014-07-21 | 2016-01-28 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Zaltoprofen and muscle relaxant combinations |
| EP3197434A1 (en) | 2014-09-24 | 2017-08-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Loxoprofen and antispastic drug combinations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3012837A1 (de) * | 1979-04-10 | 1980-10-30 | Sandoz Ag | Analgetische und myotonolytische praeparate |
| GB2135884B (en) * | 1983-03-09 | 1986-09-17 | Sandoz Ltd | Analgesic preparations containing tizanidine and paracetamol |
| US4571400A (en) * | 1984-12-18 | 1986-02-18 | Belleview Pharmaceutical, Inc. | Dihydrocodeine/ibuprofen pharmaceutical compositions and method |
-
1987
- 1987-10-22 HU HU874740A patent/HUT47849A/hu unknown
- 1987-10-22 NL NL8702523A patent/NL8702523A/nl not_active Application Discontinuation
- 1987-10-30 FR FR878715185A patent/FR2605884B1/fr not_active Expired
- 1987-10-30 BE BE8701237A patent/BE1000265A3/fr not_active IP Right Cessation
- 1987-10-30 GB GB08725538A patent/GB2197198A/en not_active Withdrawn
- 1987-10-30 LU LU87033A patent/LU87033A1/fr unknown
- 1987-10-30 IT IT8748554A patent/IT8748554A0/it unknown
- 1987-10-30 SE SE8704240A patent/SE8704240L/xx not_active Application Discontinuation
- 1987-11-02 JP JP62278987A patent/JPS63132834A/ja active Pending
- 1987-11-02 AU AU80575/87A patent/AU8057587A/en not_active Abandoned
- 1987-11-02 KR KR870012244A patent/KR890007728A/ko not_active Application Discontinuation
- 1987-11-02 IL IL84344A patent/IL84344A0/xx unknown
- 1987-11-02 DD DD308577A patent/DD300508A5/de unknown
- 1987-11-02 DK DK574187A patent/DK574187A/da not_active Application Discontinuation
- 1987-11-02 GR GR871678A patent/GR871678B/el unknown
- 1987-11-02 PT PT86061A patent/PT86061B/pt not_active IP Right Cessation
- 1987-11-03 ZA ZA878257A patent/ZA878257B/xx unknown
- 1987-11-03 PH PH36018A patent/PH23276A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2605884A1 (fr) | 1988-05-06 |
| PT86061A (en) | 1987-12-01 |
| KR890007728A (ko) | 1989-07-05 |
| HUT47849A (en) | 1989-04-28 |
| IL84344A0 (en) | 1988-04-29 |
| BE1000265A3 (fr) | 1988-09-27 |
| NL8702523A (nl) | 1988-06-01 |
| DK574187A (da) | 1988-05-04 |
| GB8725538D0 (en) | 1987-12-02 |
| FR2605884B1 (fr) | 1989-05-05 |
| DK574187D0 (da) | 1987-11-02 |
| SE8704240L (sv) | 1988-05-04 |
| GB2197198A (en) | 1988-05-18 |
| PT86061B (pt) | 1990-11-07 |
| IT8748554A0 (it) | 1987-10-30 |
| AU8057587A (en) | 1988-05-05 |
| SE8704240D0 (sv) | 1987-10-30 |
| LU87033A1 (fr) | 1988-05-03 |
| PH23276A (en) | 1989-06-23 |
| GR871678B (en) | 1988-03-03 |
| DD300508A5 (de) | 1992-06-17 |
| ZA878257B (en) | 1989-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8895066B2 (en) | Bilayer composition for the sustained release of acetaminophen and tramadol | |
| US4375468A (en) | Constant order release aspirin composition and method of treating arthritis | |
| JP2638389B2 (ja) | 経口投与後のインダパミドの徐放性マトリックス錠剤 | |
| JPH04501425A (ja) | ロラタジン、イブプロフェンおよびプソイドエフェドリンを含む薬剤組成物 | |
| JPS62292720A (ja) | 制御放出型ジヒドロコデイン組成物 | |
| MXPA05002827A (es) | Formulaciones farmaceuticas de modafinil. | |
| KR20100020480A (ko) | Ｄｐｐ-ｉｖ 저해제를 위한 안정한 약제학적 제제 | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| KR100202154B1 (ko) | 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제 | |
| JP5828609B2 (ja) | 持続性解熱鎮痛消炎剤 | |
| JPS63132834A (ja) | 鎮静剤製剤 | |
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| JP2588191B2 (ja) | 悪性腫瘍および重症ウイルス感染症に伴う神経症状を改善するための治療剤 | |
| JPS59170014A (ja) | 鎮痛剤 | |
| JP6042886B2 (ja) | 早漏症治療用の薬学組成物 | |
| Brown et al. | Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis | |
| RU2101014C1 (ru) | Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения | |
| GB2135884A (en) | Analgesic preparations containing tizanidine and paracetamol | |
| JP2000229853A (ja) | 生理痛改善用組成物 | |
| WO2017211182A1 (zh) | 一种预防或治疗炎性疾病的药物组合物 | |
| AU777223B2 (en) | Medicaments | |
| JPS60174718A (ja) | ロラゼパム含有睡眠薬 | |
| Martens | Double-blind randomized comparison of proglumetacin and naproxen sodium in the treatment of patients with ankle sprains | |
| RU2121347C1 (ru) | Лекарственный препарат | |
| JPH07188004A (ja) | 感冒薬 |